Contrary to previous clinical trial findings, researchers have found that monthly injections that counteract age-related macular degeneration may not be required by patients. The research is being presented at the 2014 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Orlando, Fla.
The investigators used a strategy called "treat and extend" to conduct the study, in which the frequency of office visits and injections were tailored to each patient's individual response to therapy. Following 185 patients over a three-and-a-half-year period, the average number of visits and injections was reduced from 12 to 8.3 times per year.
AdvertisementAMD is the leading cause of severe vision loss among people 50 years of age or older in industrialized countries. The findings could reduce the burden associated with frequent therapy, lowering the financial burdens on patients, families and government.
P Incarceration of Black Male can Compromise Research Studies Consistent Safety is Not Possible Even With Improved Sources of Water M
You May Also Like